|
시장보고서
상품코드
2100178
강박성 장애 치료제 시장 : 시장 예측(2026-2032년)Obsessive-Compulsive Disorder Drugs Market - Global Forecast 2026-2032 |
||||||
360iResearch
강박성 장애 치료제 시장은 2032년까지 연평균 복합 성장률(CAGR) 8.91%로 19억 1,000만 달러에 달할 것으로 예측됩니다.
| 주요 시장 통계 | |
|---|---|
| 기준 연도 : 2025년 | 10억 5,000만 달러 |
| 추정 연도 : 2026년 | 11억 3,000만 달러 |
| 예측 연도 : 2032년 | 19억 1,000만 달러 |
| CAGR(%) | 8.91% |
강박장애 치료제는 침입적 사고나 반복적 행동을 특징으로 하며, 만성적이고 종종 일상생활에 지장을 주는 정신 질환의 치료에서 중심적인 역할을 하고 있습니다. 현재의 약물 요법은 선택적 세로토닌 재흡수 억제제(SSRI)를 핵심으로 하고 있으며, 부분적인 반응이나 불충분한 반응을 보이는 환자에 대해서는 클로미프라민이나 근거에 기반한 병용 요법이 사용되고 있습니다. 세계보건기구(WHO)가 정신 질환을 전 세계 장애의 주요 원인 중 하나로 인식하고 있으며, 또한, 동료 심사를 거친 역학 연구에서 강박장애(OCD)가 사춘기나 청년기에 발병하는 경우가 많으며, 장기적인 관리가 필요한 질환이라는 점이 일관되게 지적되고 있는 만큼, 강박장애 치료제의 임상적 의의는 더욱 커지고 있습니다.
업계 환경은 진단율 상승, 정신 건강에 대한 인식 제고, 원격 정신의료의 확대, 그리고 약물 치료와 인지행동치료(특히 노출 치료 및 반응 예방 치료) 간의 더욱 견고한 통합에 의해 형성되고 있습니다. 한편, 진단 지연, 치료 효과의 편차, 부작용의 부담, 재발 위험, 동반되는 우울증 및 불안 장애, 그리고 자원이 부족한 지역에서의 의료 접근성 격차 등 여전히 충족되지 않은 미충족 요구는 막대합니다. 의료 시스템이 정밀 정신의학으로 전환되는 가운데, 강박장애 치료제 관련 이해관계자들은 차별화된 작용기전, 복약 순응도를 지원하는 제형, 실세계 데이터, 디지털 모니터링, 그리고 환자 중심의 치료 결과를 최우선 과제로 삼고 있습니다.
OCD 치료 전망의 혁신적인 변화
강박장애(OCD) 치료제 분야는 증상 억제에서 벗어나, 보다 개인화되고 근거 기반의 치료 경로로 서서히 그러나 의미 있는 변화를 겪고 있습니다. 표준 세로토닌계 치료법이 여전히 기초를 이루고 있지만, 임상 현장에서는 치료 저항성 강박장애를 조기에 식별하고, 지침에서 권장하는 특정 사례에 대해 항정신병제를 이용한 증강 요법을 포함한 구조화된 증강 접근법을 적용하는 데 점점 더 중점을 두고 있습니다. 이러한 변화는 치료 반응을 평가하고 치료 최적화를 이끌어내기 위한 ‘예일-브라운 강박장애 척도(Yale-Brown Obsessive Compulsive Scale)’와 같은 표준화된 중증도 평가 도구의 활용 확대에 힘입고 있습니다.
강박장애(OCD) 신약 개발에서 인공지능(AI)의 누적 영향
인공지능(AI)은 신약 발굴, 개발, 임상 업무, 치료 후 모니터링에 이르기까지 강박장애(OCD) 치료제 생태계에 점점 더 큰 영향을 미치고 있습니다. 초기 연구 단계에서는 AI를 활용한 분석을 통해 표적 식별, 문헌 마이닝, 분자 스크리닝, 그리고 기존의 세로토닌 재흡수 억제제를 넘어서는 새로운 작용기전의 탐색이 지원됩니다. 임상 개발 단계에서는 머신러닝 기법이 환자 계층화 개선, 동반 질환 패턴 파악, 임상시험 피험자 모집 최적화, 그리고 치료 반응 및 이상 반응과 관련된 신호 감지에 활용되고 있습니다.
OCD 치료제 시장의 주요 지역별 인사이트
북미의 강박장애 치료제 시장 환경은 확립된 정신과 지침, 선택적 세로토닌 재흡수 억제제(SSRI)의 광범위한 접근성, 전문적인 정신건강 인프라, 그리고 경과 관찰 및 복약 관리에서 원격의료의 활용 확대와 같은 요인들로부터 혜택을 받고 있습니다. 미국과 캐나다에서는 인지행동치료와 결합된 근거 기반 약물 요법이 계속해서 중시되고 있지만, 보험사의 심층 검토, 보험 제도 설계, 지방 지역의 접근 장벽, 그리고 정신건강 전문가의 분포가 치료의 지속성에 영향을 미치고 있습니다.
강박장애 치료제 접근성 및 정책에 관한 주요 그룹별 인사이트
아세안(ASEAN) 국가들에서는 회원국들이 정신건강 정책 체계, 도시 지역의 의료 서비스 제공 역량, 그리고 제네릭 항우울제에 대한 접근성을 확대함에 따라 강박장애 치료제의 중요성이 점점 더 커지고 있습니다. 그러나 특히 대도시권 이외의 지역에서는 진단 누락과 정신과 의료 서비스의 불균형한 분포가 여전히 치료 수용 상황에 영향을 미치고 있습니다. GCC 국가에서는 의료 서비스의 현대화, 보험 제도의 확충, 전문적인 행동 의료 서비스에 대한 투자가 진행되면서 강박장애 진단 및 약물 치료를 위한 보다 견고한 기반이 마련되고 있지만, 문화적 낙인은 여전히 중요한 고려 사항으로 남아 있습니다.
강박장애 치료제 도입에 관한 주요 국가 인사이트
미국은 활발한 임상 연구 활동, 지침에 기반한 SSRI의 광범위한 사용, 원격 정신의료의 높은 보급률, 그리고 치료 저항성 강박장애에 대한 적극적인 대응을 통해 강박장애 치료제 분야에서 여전히 매우 영향력 있는 국가입니다. 치료 접근성은 보험 적용 범위, 사전 승인, 전문의 확보, 그리고 높은 동반 질환 관리 필요성에 따라 좌우됩니다. 캐나다에서는 공공 지침에 기반한 의료 접근성, 근거 기반 처방, 정신건강 서비스의 통합이 중시되고 있으나, 정신과 의료 분야에서 주별 차이 및 지역 간 격차가 적시 치료에 영향을 미치고 있습니다. 멕시코에서는 합리적인 가격의 제네릭 의약품에 대한 인식과 사용이 확대되고 있지만, 전문의에 대한 접근성 및 치료의 지속성에 대해서는 여전히 불균형한 상황이 지속되고 있습니다.
OCD 의약품 업계 리더를 위한 실천적 제안
업계 리더는 강박장애 치료에서 가장 뿌리 깊은 미충족 요구, 즉 불충분한 치료 반응, 효과 발현 지연, 재발 예방, 성기능 장애, 체중 변화, 진정 작용 및 복약 순응도 문제 등에 대처하는 차별화된 치료 프로파일을 우선시해야 합니다. 개발 프로그램에는 실제 임상 현장에서의 임상적 관련성을 입증하기 위해, 검증된 OCD 특이적 평가 지표, 환자 보고 결과, 동반 질환 평가, 안전성 모니터링 및 장기 추적 조사 설계를 포함해야 합니다.
증거 기반 강박장애(OCD) 치료제 분석을 위한 조사 방법론
본 요약 보고서는 검증된 공개 정보 및 과학적 정보원을 바탕으로 한 체계적인 2차 조사 방법론을 사용하여 작성되었습니다. 이 조사 접근 방식은 동료 심사를 거친 정신의학 문헌, 임상 실무 지침, 규제 당국의 발표, 의약품 안전성 감시(약물감시) 자료, 공중보건 관련 간행물, 필수 의약품에 관한 참고 문헌 및 정신건강 정책 문서에서 얻은 근거를 통합합니다. 특히, 질병 부담, 치료 기준, 약물 분류, 접근성, 규제상 고려 사항 및 지역별 의료 인프라에 관한 데이터에 기반한 인사이트에 중점을 두고 있습니다.
강박장애 치료제의 미래에 관한 결론
강박장애 치료제 분야는 기존의 세로토닌 중심 치료 모델에서 보다 통합적이고 환자 개개인에 맞춘 치료 생태계로 진화하고 있습니다. 기존 약물은 여전히 필수적이지만, 업계의 다음 단계 발전은 치료 저항성 강박장애의 보다 적절한 관리, 내약성 향상, 더 신속하고 지속적인 치료 효과, 실세계 데이터(REW)의 창출, 그리고 약물 요법과 행동 요법 간의 보다 견고한 연계로 정의될 것입니다.
자주 묻는 질문
목차
제1장 서문
제2장 조사 방법
제3장 주요 요약
제4장 시장 개요
제5장 시장 인사이트
제6장 AI의 누적 영향, 2026년
제7장 강박성 장애 치료제 시장 : 약제 클래스별
제8장 강박성 장애 치료제 시장 : 유통 채널별
제9장 강박성 장애 치료제 시장 : 투여 경로별
제10장 강박성 장애 치료제 시장 : 최종사용자별
제11장 강박성 장애 치료제 시장 : 요법 유형별
제12장 강박성 장애 치료제 시장 : 지역별
제13장 강박성 장애 치료제 시장 : 그룹별
제14장 강박성 장애 치료제 시장 : 국가별
제15장 경쟁 구도
제16장 기업 개요
LSHThe Obsessive-Compulsive Disorder Drugs Market is projected to grow by USD 1.91 billion at a CAGR of 8.91% by 2032.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2025] | USD 1.05 billion |
| Estimated Year [2026] | USD 1.13 billion |
| Forecast Year [2032] | USD 1.91 billion |
| CAGR (%) | 8.91% |
Obsessive-compulsive disorder drugs are central to the treatment of a chronic and often disabling mental health condition characterized by intrusive thoughts and repetitive behaviors. Current pharmacotherapy is anchored by selective serotonin reuptake inhibitors, with clomipramine and evidence-based augmentation strategies used for patients with partial or inadequate response. The clinical relevance of the obsessive-compulsive disorder drugs landscape is reinforced by the World Health Organization's recognition of mental disorders as a major contributor to global disability, while peer-reviewed epidemiology consistently identifies OCD as a condition that frequently begins in adolescence or early adulthood and often requires long-term care.
The industry environment is shaped by rising diagnosis rates, improving mental health awareness, expanding telepsychiatry, and stronger integration of pharmacological treatment with cognitive behavioral therapy, particularly exposure and response prevention. At the same time, unmet needs remain substantial, including delayed diagnosis, variable treatment response, adverse-event burden, relapse risk, comorbid depression and anxiety, and access gaps across low-resource settings. As healthcare systems move toward precision psychiatry, stakeholders in obsessive-compulsive disorder therapeutics are prioritizing differentiated mechanisms, adherence-supportive formulations, real-world evidence, digital monitoring, and patient-centered outcomes.
Transformative Shifts in the OCD Therapeutics Landscape
The obsessive-compulsive disorder drugs landscape is undergoing a gradual but meaningful transformation from symptom suppression toward more individualized, evidence-informed treatment pathways. Standard serotonin-based therapies remain foundational, yet clinical practice is increasingly focused on identifying treatment-resistant OCD earlier and applying structured augmentation approaches, including antipsychotic augmentation in selected cases where supported by guidelines. This shift is supported by greater use of standardized severity tools, such as the Yale-Brown Obsessive Compulsive Scale, to evaluate response and guide therapy optimization.
Another major shift is the movement from episodic prescribing to integrated care models. Pharmacotherapy is increasingly coordinated with psychotherapy, digital behavioral support, remote follow-up, and comorbidity management. Regulators and payers are also emphasizing safety, adherence, pharmacovigilance, and real-world effectiveness rather than relying only on controlled trial endpoints. Meanwhile, scientific interest in glutamatergic modulation, neuroinflammation, rapid-acting neuropsychiatric approaches, and biomarker-guided treatment is broadening the future development agenda. These changes are creating a more competitive environment for OCD drug development, where clinical differentiation depends on tolerability, speed of response, relapse prevention, and effectiveness in patients who do not respond adequately to first-line therapies.
Cumulative Impact of Artificial Intelligence on OCD Drug Development
Artificial intelligence is increasingly influencing the obsessive-compulsive disorder drugs ecosystem across discovery, development, clinical operations, and post-treatment monitoring. In early research, AI-enabled analytics can support target identification, literature mining, molecular screening, and the exploration of novel mechanisms beyond conventional serotonin reuptake inhibition. In clinical development, machine learning methods are being applied to improve patient stratification, identify comorbidity patterns, optimize trial recruitment, and detect signals associated with treatment response or adverse events.
In care delivery, AI-supported tools can help clinicians monitor symptom trajectories, medication adherence, relapse indicators, and patient-reported outcomes between appointments. Natural language processing, when applied responsibly to clinical notes or structured patient inputs, may help identify severity changes, compulsive behavior patterns, or risk factors that require timely intervention. However, the cumulative impact of artificial intelligence depends on strong governance. OCD treatment involves sensitive behavioral and mental health data, making privacy protection, bias mitigation, clinical validation, explainability, and regulatory compliance essential. AI is therefore best positioned as a decision-support layer that strengthens evidence generation and continuity of care, not as a replacement for specialist clinical judgment.
Key Regional Insights Across the OCD Drugs Market
In North America, the obsessive-compulsive disorder drugs landscape benefits from established psychiatric guidelines, broad availability of selective serotonin reuptake inhibitors, specialist mental health infrastructure, and increasing use of telehealth for follow-up and medication management. The United States and Canada continue to emphasize evidence-based pharmacotherapy combined with cognitive behavioral therapy, while payer scrutiny, insurance design, rural access barriers, and mental health workforce distribution influence treatment continuity.
Europe is characterized by strong clinical governance, national health technology assessment processes, and high emphasis on safety monitoring, guideline adherence, and equitable mental health access. Countries across Western Europe have mature prescribing environments for OCD medications, while variation in reimbursement, psychotherapy waiting times, and mental health workforce capacity influences patient access across the wider region. Asia-Pacific is marked by rising recognition of OCD, expanding psychiatric services, digital health adoption, and growing demand for affordable pharmacological treatment, particularly in China, India, Japan, South Korea, Australia, and ASEAN economies. However, stigma, uneven specialist availability, and out-of-pocket expenditure continue to affect diagnosis and adherence in several settings.
Latin America shows increasing mental health awareness and expanding use of generic antidepressants, with Brazil and Mexico playing important roles in regional treatment access. Nonetheless, fragmented healthcare delivery, socioeconomic inequality, and variable specialist availability remain barriers to consistent OCD management. In the Middle East, investment in mental health infrastructure is improving access in Gulf economies, while awareness campaigns are helping reduce stigma and support earlier care-seeking. Across Africa, the OCD drugs landscape is shaped by significant access challenges, limited psychiatric workforce density in many countries, and dependence on essential medicines frameworks, making affordability, primary care integration, task-sharing, and community-based mental health services critical priorities.
Key Group Insights for OCD Drug Access and Policy
ASEAN is becoming increasingly relevant for obsessive-compulsive disorder drugs as member countries expand mental health policy frameworks, urban healthcare capacity, and access to generic antidepressants. However, diagnosis gaps and uneven psychiatric service distribution continue to shape treatment uptake, particularly outside major cities. The GCC is advancing through healthcare modernization, insurance expansion, and investment in specialized behavioral health services, creating stronger pathways for OCD diagnosis and pharmacological treatment while cultural stigma remains an important consideration.
The European Union provides a structured environment for OCD drug access through centralized regulatory standards, pharmacovigilance systems, and national reimbursement mechanisms. Its emphasis on mental health policy, patient safety, and real-world evidence supports consistent therapeutic evaluation across member states, even as reimbursement timelines differ. BRICS economies collectively represent diverse OCD drug dynamics, with China and India facing large access and affordability challenges, Brazil strengthening public and private mental health delivery, Russia maintaining a specialist-led treatment environment, and South Africa confronting workforce and equity constraints.
The G7 group is characterized by advanced regulatory systems, established clinical guidelines, high adoption of evidence-based psychiatric medicines, and strong post-marketing safety expectations, making it influential in clinical standards for OCD therapeutics. NATO countries overlap significantly with advanced North American and European healthcare systems, where mental health preparedness, service resilience, essential medicine availability, and pharmaceutical supply continuity are increasingly relevant policy considerations. Across these groups, the shared strategic themes are affordability, guideline-based prescribing, treatment-resistant OCD management, real-world outcomes, pharmacovigilance, and integration of medication with behavioral therapy.
Key Country Insights in Obsessive-Compulsive Disorder Drug Adoption
The United States remains a highly influential country for obsessive-compulsive disorder drugs due to strong clinical research activity, broad use of guideline-supported SSRIs, high telepsychiatry adoption, and active attention to treatment-resistant OCD. Access is shaped by insurance coverage, prior authorization, specialist availability, and high comorbidity management needs. Canada emphasizes publicly guided healthcare access, evidence-based prescribing, and mental health service integration, though provincial variation and regional disparities in psychiatric care influence timely treatment. Mexico is seeing expanding awareness and use of affordable generic medicines, while access to specialists and continuity of care remain uneven.
Brazil has a significant role in Latin American OCD treatment through its public health system and private sector, with antidepressant access supported by generic availability but constrained by regional disparities. The United Kingdom relies on structured clinical guidance, primary care pathways, and specialist mental health services, with stepped-care models supporting pharmacological and psychological treatment. Germany, France, Italy, and Spain maintain mature psychiatric prescribing environments, broad access to established OCD medications, and strong safety oversight, although waiting times for psychotherapy can affect integrated care. Russia has specialist psychiatric infrastructure and established antidepressant use, but regional access variation affects consistency of care.
China is experiencing rising mental health recognition, urban psychiatric service expansion, and growing use of evidence-based pharmacotherapy, while rural access and stigma remain barriers. India faces substantial unmet need because of diagnosis delays, limited specialist density, and affordability concerns, yet generic drug availability and digital health expansion are improving reach. Japan has a well-developed healthcare system and structured prescribing practices, with continued focus on safety and tolerability. Australia combines evidence-based mental health policy, primary care involvement, and telehealth-supported access, especially for geographically dispersed populations. South Korea is advancing mental health service capacity and digital care adoption, while stigma and high academic and occupational stress environments influence care-seeking behavior.
Actionable Recommendations for OCD Drug Industry Leaders
Industry leaders should prioritize differentiated therapeutic profiles that address the most persistent unmet needs in obsessive-compulsive disorder treatment, including inadequate response, delayed onset of benefit, relapse prevention, sexual dysfunction, weight change, sedation, and adherence challenges. Development programs should incorporate validated OCD-specific endpoints, patient-reported outcomes, comorbidity assessment, safety monitoring, and longer follow-up designs to demonstrate real-world clinical relevance.
Stakeholders should invest in precision psychiatry capabilities, including biomarker exploration, digital phenotyping, and AI-supported patient stratification, while maintaining rigorous ethical and regulatory standards. Partnerships with clinical networks can improve recruitment of diverse patient populations, including adolescents, adults with comorbid depression or anxiety, and individuals with treatment-resistant symptoms. Commercial and access teams should strengthen education for primary care physicians, psychiatrists, pharmacists, and caregivers to improve early diagnosis and guideline-concordant treatment.
Regional strategies should reflect local realities: affordability and generic access are critical in emerging economies, while evidence differentiation and health-economic justification are increasingly important in highly regulated markets. Leaders should also support integrated treatment models that combine medication with cognitive behavioral therapy, adherence tools, relapse monitoring, and culturally appropriate patient engagement. Supply resilience, pharmacovigilance, transparent evidence communication, and responsible digital integration will remain essential to sustaining trust in OCD pharmacotherapy.
Research Methodology for Evidence-Based OCD Drug Analysis
This executive summary is developed using a structured secondary research methodology grounded in verified public and scientific sources. The research approach synthesizes evidence from peer-reviewed psychiatric literature, clinical practice guidelines, regulatory agency communications, pharmacovigilance resources, public health publications, essential medicines references, and mental health policy documentation. Emphasis is placed on data-backed insights related to disease burden, treatment standards, drug classes, access dynamics, regulatory considerations, and regional healthcare infrastructure.
The analysis applies triangulation across clinical, regulatory, and health-system evidence to ensure consistency and reliability. Information is evaluated for source credibility, recency, therapeutic relevance, and applicability to obsessive-compulsive disorder pharmacotherapy. Regional, group, and country insights are interpreted through healthcare access, reimbursement, psychiatric workforce availability, mental health awareness, medicine availability, and telehealth adoption rather than market sizing or forecasting. The methodology excludes speculative estimates and avoids unsupported claims, focusing instead on observable treatment trends, evidence-based clinical practice, and policy-relevant market dynamics.
Conclusion on the Future of Obsessive-Compulsive Disorder Drugs
The obsessive-compulsive disorder drugs landscape is advancing from a conventional serotonin-centered treatment model toward a more integrated and patient-specific therapeutic ecosystem. Established medications remain essential, but the next phase of industry progress will be defined by better management of treatment-resistant OCD, improved tolerability, faster and more durable response, real-world evidence generation, and stronger coordination between pharmacotherapy and behavioral interventions.
Regional differences in access, stigma, affordability, specialist capacity, and reimbursement will continue to shape adoption patterns. Artificial intelligence, digital monitoring, and precision psychiatry can enhance research and care delivery when supported by clinical validation and responsible data governance. For industry participants, the most sustainable opportunities lie in clinically meaningful innovation, inclusive evidence generation, ethical technology use, pharmacovigilance strength, and access strategies that reflect local healthcare realities. By addressing unmet patient needs while aligning with evolving standards of mental health care, stakeholders can contribute to more effective and equitable OCD treatment worldwide.
Table of Contents
1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Definition
- 1.3. Market Segmentation & Coverage
- 1.4. Years Considered for the Study
- 1.5. Currency Considered for the Study
- 1.6. Language Considered for the Study
- 1.7. Key Stakeholders
2. Research Methodology
- 2.1. Introduction
- 2.2. Research Design
- 2.2.1. Primary Research
- 2.2.2. Secondary Research
- 2.3. Research Framework
- 2.3.1. Qualitative Analysis
- 2.3.2. Quantitative Analysis
- 2.4. Market Size Estimation
- 2.4.1. Top-Down Approach
- 2.4.2. Bottom-Up Approach
- 2.5. Data Triangulation
- 2.6. Research Outcomes
- 2.7. Research Assumptions
- 2.8. Research Limitations
3. Executive Summary
- 3.1. Introduction
- 3.2. CXO Perspective
- 3.3. Market Size & Growth Trends
- 3.4. New Revenue Opportunities
- 3.5. Next-Generation Business Models
- 3.6. Industry Roadmap
4. Market Overview
- 4.1. Introduction
- 4.2. Industry Ecosystem & Value Chain Analysis
- 4.2.1. Supply-Side Analysis
- 4.2.2. Demand-Side Analysis
- 4.2.3. Stakeholder Analysis
- 4.3. Market Dynamics
- 4.3.1. Key Drivers
- 4.3.2. Key Restraints
- 4.3.3. Key Opportunities
- 4.3.4. Key Challenges
- 4.4. Porter's Five Forces Analysis
- 4.5. PESTLE Analysis
- 4.6. Market Outlook
- 4.6.1. Near-Term Market Outlook (0-2 Years)
- 4.6.2. Medium-Term Market Outlook (3-5 Years)
- 4.6.3. Long-Term Market Outlook (5-10 Years)
- 4.7. Go-to-Market Strategy
5. Market Insights
- 5.1. Consumer Insights & End-User Perspective
- 5.2. Consumer Experience Benchmarking
- 5.3. Opportunity Mapping
- 5.4. Distribution Channel Analysis
- 5.5. Pricing Trend Analysis
- 5.6. Regulatory Compliance & Standards Framework
- 5.7. ESG & Sustainability Analysis
- 5.8. Disruption & Risk Scenarios
- 5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Obsessive-Compulsive Disorder Drugs Market, by Drug Class
- 7.1. Introduction
- 7.2. MAOIs
- 7.2.1. Phenelzine
- 7.2.2. Tranylcypromine
- 7.3. SNRIs
- 7.3.1. Desvenlafaxine
- 7.3.2. Duloxetine
- 7.3.3. Venlafaxine
- 7.4. SSRIs
- 7.4.1. Citalopram
- 7.4.2. Fluoxetine
- 7.4.3. Fluvoxamine
- 7.4.4. Paroxetine
- 7.4.5. Sertraline
- 7.5. TCAs
- 7.5.1. Amitriptyline
- 7.5.2. Clomipramine
- 7.5.3. Imipramine
8. Obsessive-Compulsive Disorder Drugs Market, by Distribution Channel
- 8.1. Introduction
- 8.2. Offline
- 8.3. Online
- 8.3.1. eCommerce Website
- 8.3.2. Manufacturer Website
9. Obsessive-Compulsive Disorder Drugs Market, by Route Of Administration
- 9.1. Introduction
- 9.2. Oral
- 9.3. Parenteral
10. Obsessive-Compulsive Disorder Drugs Market, by End User
- 10.1. Introduction
- 10.2. Clinics
- 10.3. Hospitals
- 10.4. Households
11. Obsessive-Compulsive Disorder Drugs Market, by Therapy Type
- 11.1. Introduction
- 11.2. Monotherapy
- 11.3. Combination Therapy
- 11.4. Adjunctive Therapy
12. Obsessive-Compulsive Disorder Drugs Market, by Region
- 12.1. Asia-Pacific
- 12.2. North America
- 12.3. Latin America
- 12.4. Europe
- 12.5. Middle East
- 12.6. Africa
13. Obsessive-Compulsive Disorder Drugs Market, by Group
- 13.1. ASEAN
- 13.2. GCC
- 13.3. European Union
- 13.4. BRICS
- 13.5. G7
- 13.6. NATO
14. Obsessive-Compulsive Disorder Drugs Market, by Country
- 14.1. United States
- 14.2. Canada
- 14.3. Mexico
- 14.4. Brazil
- 14.5. United Kingdom
- 14.6. Germany
- 14.7. France
- 14.8. Russia
- 14.9. Italy
- 14.10. Spain
- 14.11. China
- 14.12. India
- 14.13. Japan
- 14.14. Australia
- 14.15. South Korea
15. Competitive Landscape
- 15.1. Market Share Analysis, 2025
- 15.2. FPNV Positioning Matrix, 2025
- 15.3. Market Concentration Analysis, 2025
- 15.3.1. Concentration Ratio (CR)
- 15.3.2. Herfindahl Hirschman Index (HHI)
- 15.4. Recent Developments & Impact Analysis, 2025
- 15.5. Product Portfolio Analysis, 2025
- 15.6. Benchmarking Analysis, 2025
16. Company Profiles
- 16.1. AbbVie Inc
- 16.2. Alembic Pharmaceuticals Ltd
- 16.3. Amneal Pharmaceuticals Inc
- 16.4. Apotex Inc
- 16.5. AstraZeneca PLC
- 16.6. Aurobindo Pharma Limited
- 16.7. Biogen Inc
- 16.8. Biohaven Ltd
- 16.9. Bristol-Myers Squibb Company
- 16.10. Cipla Limited
- 16.11. Dr Reddys Laboratories Ltd
- 16.12. Eli Lilly and Company
- 16.13. GlaxoSmithKline plc
- 16.14. Glenmark Pharmaceuticals Limited
- 16.15. H Lundbeck AS
- 16.16. Intas Pharmaceuticals Limited
- 16.17. Jazz Pharmaceuticals Plc
- 16.18. Johnson & Johnson
- 16.19. Lupin Ltd
- 16.20. Merck & Co Inc
- 16.21. Novartis AG
- 16.22. Otsuka Pharmaceutical Co Ltd
- 16.23. Pfizer Inc
- 16.24. Sun Pharmaceutical Industries Ltd
- 16.25. Takeda Pharmaceutical Company Limited
- 16.26. Teva Pharmaceutical Industries Ltd
- 16.27. Torrent Pharmaceuticals Limited
- 16.28. Viatris Inc
- 16.29. Wockhardt Ltd
